See more : ParaFin Corporation (PFNO) Income Statement Analysis – Financial Results
Complete financial analysis of Progyny, Inc. (PGNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Progyny, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Yashraj Containeurs Limited (YASHRAJC.BO) Income Statement Analysis – Financial Results
- PT Singaraja Putra Tbk (SINI.JK) Income Statement Analysis – Financial Results
- Goodfellow Inc. (GDL.TO) Income Statement Analysis – Financial Results
- Kallebäck Property Invest AB (publ) (KAPIAB.ST) Income Statement Analysis – Financial Results
- PT Asia Pacific Fibers Tbk (POLY.JK) Income Statement Analysis – Financial Results
Progyny, Inc. (PGNY)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.progyny.com
About Progyny, Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.09B | 786.91M | 500.62M | 344.86M | 229.68M | 105.40M | 48.58M |
| Cost of Revenue | 849.80M | 619.59M | 388.49M | 274.80M | 184.18M | 85.97M | 41.18M |
| Gross Profit | 238.80M | 167.33M | 112.14M | 70.06M | 45.51M | 19.43M | 7.40M |
| Gross Profit Ratio | 21.94% | 21.26% | 22.40% | 20.32% | 19.81% | 18.44% | 15.23% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 117.13M | 98.33M | 59.62M | 46.71M | 23.93M | 15.60M | 14.15M |
| Selling & Marketing | 59.49M | 45.66M | 20.18M | 15.01M | 11.90M | 7.29M | 4.26M |
| SG&A | 176.62M | 143.98M | 79.80M | 61.71M | 35.83M | 22.89M | 18.41M |
| Other Expenses | 0.00 | 286.00K | -366.00K | 210.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 176.62M | 143.98M | 79.80M | 61.71M | 35.83M | 22.89M | 18.41M |
| Cost & Expenses | 1.03B | 763.57M | 468.28M | 336.51M | 220.01M | 108.85M | 59.59M |
| Interest Income | 0.00 | 814.00K | 461.00K | 121.00K | 58.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 814.00K | 461.00K | 121.00K | 58.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 2.28M | 1.60M | 1.30M | 1.91M | 2.13M | 1.88M | 1.56M |
| EBITDA | 64.47M | 24.94M | 33.64M | 10.25M | 11.81M | -1.57M | -9.45M |
| EBITDA Ratio | 5.92% | 3.17% | 6.72% | 2.97% | 13.06% | 1.30% | -17.97% |
| Operating Income | 62.18M | 23.34M | 32.34M | 8.35M | 27.85M | -3.45M | -11.01M |
| Operating Income Ratio | 5.71% | 2.97% | 6.46% | 2.42% | 12.13% | -3.28% | -22.65% |
| Total Other Income/Expenses | 8.51M | 1.10M | 95.00K | 331.00K | -18.23M | -3.44M | -1.45M |
| Income Before Tax | 70.69M | 24.44M | 32.44M | 8.68M | -8.56M | -6.89M | -12.46M |
| Income Before Tax Ratio | 6.49% | 3.11% | 6.48% | 2.52% | -3.73% | -6.54% | -25.64% |
| Income Tax Expense | 8.65M | -5.92M | -33.33M | -37.78M | 12.00K | -1.78M | -3.00K |
| Net Income | 62.04M | 30.36M | 65.77M | 46.46M | -8.57M | 661.00K | -12.45M |
| Net Income Ratio | 5.70% | 3.86% | 13.14% | 13.47% | -3.73% | 0.63% | -25.63% |
| EPS | 0.65 | 0.33 | 0.74 | 0.54 | -0.10 | 0.01 | -0.18 |
| EPS Diluted | 0.62 | 0.30 | 0.66 | 0.47 | -0.10 | 0.01 | -0.15 |
| Weighted Avg Shares Out | 95.02M | 92.20M | 89.11M | 85.72M | 83.57M | 81.56M | 70.59M |
| Weighted Avg Shares Out (Dil) | 100.67M | 99.96M | 100.36M | 99.06M | 83.57M | 81.56M | 81.56M |
Progyny (PGNY) Crashes After Losing Significant Client - Hagens Berman
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progyny, Inc. - PGNY
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Progyny, Inc. (PGNY) And Encourages Stockholders to Reach Out
Fertility-benefits provider Progyny's stock on track for biggest-ever decline after losing ‘significant' client
Why Progyny Stock Is Crashing Today
Top 3 Health Care Stocks That Are Set To Fly This Quarter
Progyny: Downgrading As Uncertainties Increase
Progyny EPS Outperforms, Revenue Dips in Q2
Why Progyny Stock Dropped Today
Progyny, Inc. (PGNY) Q2 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports